InvestorsObserver
×
News Home

Is G1 Therapeutics Inc (GTHX) a Leader in the Biotechnology Industry?

Tuesday, October 05, 2021 01:37 PM | InvestorsObserver Analysts

Mentioned in this article

Is G1 Therapeutics Inc (GTHX) a Leader in the Biotechnology Industry?

G1 Therapeutics Inc (GTHX) is near the top in its industry group according to InvestorsObserver. GTHX gets an overall rating of 59. That means it scores higher than 59 percent of stocks. G1 Therapeutics Inc gets a 86 rank in the Biotechnology industry. Biotechnology is number 76 out of 148 industries.

Overall Score - 59
GTHX has an Overall Score of 59. Find out what this means to you and get the rest of the rankings on GTHX!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With G1 Therapeutics Inc Stock Today?

G1 Therapeutics Inc (GTHX) stock is down -4.57% while the S&P 500 has gained 1.39% as of 1:22 PM on Tuesday, Oct 5. GTHX is down -$0.60 from the previous closing price of $13.12 on volume of 1,753,494 shares. Over the past year the S&P 500 has gained 27.92% while GTHX has gained 0.72%. GTHX lost -$2.56 per share the over the last 12 months. Click Here to get the full Stock Report for G1 Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App